Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy
International Journal of Neonatal Screening · 14.08.2024 · 10 (3) · 56
DOI: 10.3390/ijns10030056 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 14.08.2024. Verfasst von Katy Cooper und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Population Health, University of Sheffield, Sheffield S1 4DA, UK. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSRD VA, UK Department of Health and Social Care.
Abstract (Originalsprache)
Spinal muscular atrophy (SMA) causes the degeneration of motor neurons in the spinal cord. Treatments including nusinersen, risdiplam, and onasemnogene abeparvovec have been shown to be effective in reducing symptoms, with recent studies suggesting greater effectiveness when treatment is initiated in the presymptomatic stage. This systematic review synthesises findings from prospective studies of presymptomatic treatment for 5q SMA published up to December 2023. The review identified three single-arm interventional studies of presymptomatic treatment (NURTURE, RAINBOWFISH, and SPR1NT), six observational studies comparing presymptomatic or screened cohorts versus symptomatic cohorts, and twelve follow-up studies of screened cohorts only (i.e., babies identified via newborn screening for SMA). Babies with three SMN2 copies met most motor milestones in the NURTURE study of nusinersen and in the SPR1NT study of onasemnogene abeparvovec. Babies with two SMN2 copies in these two studies met most motor milestones but with some delays, and some required ventilatory or feeding support. The RAINBOWFISH study of risdiplam is ongoing. Naïve comparisons of presymptomatic treatment in SPR1NT, versus untreated or symptomatic treatment cohorts, suggested improved outcomes in patients treated presymptomatically. Comparative observational studies supported the finding that presymptomatic treatment, and early treatment following screening, may improve outcomes compared with treatment at the symptomatic stage. Further research should assess the long-term clinical outcomes and cost-effectiveness of presymptomatic treatment for SMA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine and Population Health, University of Sheffield, Sheffield S1 4DA, UK.
ORCID-Profile: Katy Cooper, Jim Chilcott, Alice Bessey
Förderung
- CSRD VA
- UK Department of Health and Social Care
Zitieren
APA
Cooper, K., Nalbant, G., Sutton, A., Harnan, S., Thokala, P., Chilcott, J., McNeill, A., & Bessey, A. (2024). Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy. International Journal of Neonatal Screening, 10(3), 56. https://doi.org/10.3390/ijns10030056
Vancouver
Cooper K, Nalbant G, Sutton A, Harnan S, Thokala P, Chilcott J, et al. Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy. International Journal of Neonatal Screening. 2024;10(3):56. doi:10.3390/ijns10030056
BibTeX
@article{Cooper2024,
author = {Cooper, Katy and Nalbant, Gamze and Sutton, Anthea and Harnan, Sue and Thokala, Praveen and Chilcott, Jim and McNeill, Alisdair and Bessey, Alice},
title = {Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy},
journal = {International Journal of Neonatal Screening},
year = {2024},
volume = {10},
number = {3},
pages = {56},
doi = {10.3390/ijns10030056}
}
EUVIMED